Ropes & Gray represented Sanofi in an agreement to acquire Dren Bio’s deep B-cell depleter program, DR-0201. The targeted bispecific myeloid cell engager has the potential to reset the adaptive immune system and might lead to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases such as lupus, where significant unmet medical needs exist. The deal was announced on March 20.
Under the agreement Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totaling $1.3 billion upon achievement of certain development and launch milestones. The transaction is expected to close in the second quarter of 2025.
The Ropes & Gray team was led by life sciences licensing partner Abigail Gregor, mergers & acquisitions partner Matt Byron and IP transaction associate Dan Freshman and included tax partner Scott Pinarchick, employment & benefits partner Renata Ferrari and IP transactions counsel Joshua Talicska, mergers & acquisitions associate Alexandra Charron and IP transactions associate Giancarlo Lee.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.